Elanix Biotechnologies : annuls profit guidance and preliminary earnings for FY 2017

DGAP-Ad-hoc: Elanix Biotechnologies AG / Key word(s): Profit Warning/Change in Forecast Elanix Biotechnologies AG annuls profit guidance and preliminary earnings for FY 2017 11-Feb-2019 / 07:58 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Elanix Biotechnologies AG annuls profit guidance and preliminary earnings for FY 2017 Berlin, 11 February 2019 - In the management report for the 2016 financial year, Elanix Biotechnologies AG ("Company") had amongst others reported that sales revenues of between EUR 300,000 and EUR 500,000 are expected in the 2017 financial year. Accordingly, revenues in the amount of EUR 328,148 were reported in the preliminary consolidated financial statements for FY 2017. Both reports have been prepared and signed during the tenure of former CEO Tomas J. Svoboda Internal research of the new interim CEO has shown that this approach may be in breach of accounting rules and that the net assets, financial position and results of operations of the Company were described too positively. The Management Board therefore decided today to completely annul the earnings forecast as well as the preliminary earnings for the 2017 financial year. Currently, work is underway to prepare the annual financial statements for 2017. Additionally, other mis-management has been detected concerning outstanding loans (associated with specific conditions along with various payments without contracts) which are still under scrutiny. Lee Ann Laurent-Applegate CEO Contacts Elanix Biotechnologies AG Lee Ann Laurent-Applegate Tel: [phone] [e-mail] About Elanix Elanix develops and commercializes tissue regeneration products for acute wound care, dermatological and gynecological applications, and provides services in cell technologies. The company was founded in 2012 as a spin-out from the University Hospital of Lausanne (CHUV), Switzerland, to commercialize a patented human progenitor cell technology. Progenitor cells are fully differentiated yet immunologically neutral cells that are very potent inducers of tissue growth and healing. Forward-looking statements This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements. 11-Feb-2019 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

Language:	English
Company:	Elanix Biotechnologies AG
	Stadthausbrücke 1-3
	20355 Hamburg
	Germany
Phone:	[phone]
Fax:	[phone]
E-mail:	[e-mail]
Internet:	www.elanixbiotechnologies.com
ISIN:	DE000A0WMJQ4
WKN:	A0WMJQ
Listed:	Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf

End of Announcement	DGAP News Service

774211  11-Feb-2019 CET/CEST